Anchored Immunotherapy
The Challenge
Despite efforts to develop tumor- targeting therapies, very few are focusing on keeping drugs in the tumor microenvironment once they are there. Rapid clearance limits local drug exposure, which leads to reduced efficacy, increased systemic exposure and potential toxicity, and necessitating frequent administrations.
The Solution
Anchored Immunotherapy involves the use of anchored-drug conjugates to keep highly potent drugs at the tumor site.
Prolonged antitumor immune activation
Minimal systemic side effects from drug leakage
Need for fewer injections to achieve benefit
How Anchored-Drug Conjugates Compare to Antibody-Drug Conjugates
Antibody-Drug Conjugate
- Antibody-based delivery dependent on tumor antigen
- Suboptimal linker leads to unpredictable drug release
Anchored-Drug Conjugate
- Anchored-based delivery independent on tumor antigen
- Strong linker (binder) allows prolonged retention of drug